FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition

Pharmaceutical Research

Volumn 33, Issue 8, 2016, Pages 1833-1849

  Brenner, Mitchell C ^a   Krzyzanski, Wojciech ^b   Chou, James Z ^a   Signore, Pierre E ^a   Fung, Cyra K ^a   Guzman, David ^a   Li, Dongxia ^a   Zhang, Weihua ^a   Olsen, David R ^a   Nguyen, Viet Tam L ^a   Koo, Carolyn W ^a   Sternlicht, Mark D ^a   Lipson, Kenneth E ^a  

^a FIBROGEN INC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Connective Tissue Growth Factor; CTGF; FG 3019; TMDD

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; IODINE 125; PAMREVLUMAB; RECOMBINANT GROWTH FACTOR; RECOMBINANT HUMAN CONNECTIVE TISSUE GROWTH FACTOR; UNCLASSIFIED DRUG; CTGF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHO CELL LINE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ANIMAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG INTERACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIBODIES, MONOCLONAL; CONNECTIVE TISSUE GROWTH FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 84964049784     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-016-1918-0     Document Type: Article

References (39)

1. Holbourn KP, Acharya KR, Perbal B. The CCN family of proteins: structure-function relationships. Trends Biochem Sci. 2008;33(10):461–73.
2. Gerritsen KG, Peters HP, Nguyen TQ, Koeners MP, Wetzels JF, Joles JA, et al. Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion. Am J Physiol Renal Physiol. 2010;298(6):F1457–64.
3. Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ, Goldschmeding R. Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers. 2011;16(4):289–301.
4. Riser BL, Barnes JL, Varani J. Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer. J Cell Commun Signal. 2015;9(4):327–39.
5. ClinicalTrials.gov clinicaltrials.gov, internet communication Sep 30, 2010.
6. Wang QJ, Frazier K, Nichols B, Zhang W, Fourney P, Folz A, et al. Effects of a monoclonal antibody to connective tissue growth factor (CTGF) in experimental organ fibrosis. Am Soc Nephrol. 2002;13:315A.
7. Warshawsky I, Bu G, Schwartz AL. 39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. J Clin Invest. 1993;92(2):937–44.
8. D’Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomed Simul Resource 2009.
9. Tang C, Prueksaritanont T. Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of ‘free’ and ‘total’ drug and target. Pharm Res. 2011;28(10):2447–57.
10. Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ, Ma M, et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 2010;12(4):646–57.
11. Iadonato SP, Bu G, Maksymovitch EA, Schwartz AL. Interaction of a 39 kDa protein with the low-density-lipoprotein-receptor-related protein (LRP) on rat hepatoma cells. Biochem J. 1993;296(Pt 3):867–75.
12. Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589–96.
13. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32.
14. Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn. 2012;39(5):429–51.
15. Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2010;37(1):25–47.
16. Gillen CM, Takamata A, Mack GW, Nadel ER. Measurement of plasma volume in rats with use of fluorescent-labeled albumin molecules. J Appl Physiol (1985). 1994;76(1):485–9.
17. Bazin-Redureau MI, Renard CB, Scherrmann JM. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab′)2 and Fab after intravenous administration in the rat. J Pharm Pharmacol. 1997;49(3):277–81.
18. Singh AP, Krzyzanski W, Martin SW, Weber G, Betts A, Ahmad A, et al. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J. 2015;17(2):389–99.
19. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol. 2010;5(8):1420–8.
20. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52(2):83–124.
21. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel. 2007;10(1):84–96.
22. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53(4):853–61.
23. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst G, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol. 1995;105(2):280–4.
24. di Mola FF, Friess H, Martignoni ME, Di Sebastiano P, Zimmermann A, Innocenti P, et al. Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg. 1999;230(1):63–71.
25. de Chuva Sousa Lopes SM, Feijen A, Korving J, Korchynskyi O, Larsson J, Karlsson S, et al. Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. Dev Dyn. 2004;231(3):542–50.
26. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093–5.
27. Davda JP, Hansen RJ. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs. 2010;2(5):576–88.
28. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol. 2009;41(4):771–83.
29. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88(3):887–918.
30. Segarini PR, Nesbitt JE, Li D, Hays LG, Yates III JR, Carmichael DF. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem. 2001;276(44):40659–67.
31. Muratoglu SC, Belgrave S, Hampton B, Migliorini M, Coksaygan T, Chen L, et al. LRP1 protects the vasculature by regulating levels of connective tissue growth factor and HtrA1. Arterioscler Thromb Vasc Biol. 2013;33(9):2137–46.
32. Kawata K, Kubota S, Eguchi T, Aoyama E, Moritani NH, Kondo S, et al. Role of LRP1 in transport of CCN2 protein in chondrocytes. J Cell Sci. 2012;125(Pt 12):2965–72.
33. Marschang P, Brich J, Weeber EJ, Sweatt JD, Shelton JM, Richardson JA, et al. Normal development and fertility of knockout mice lacking the tumor suppressor gene LRP1b suggest functional compensation by LRP1. Mol Cell Biol. 2004;24(9):3782–93.
34. Kerjaschki D, Farquhar MG. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med. 1983;157(2):667–86.
35. Marzolo MP, Farfan P. New insights into the roles of megalin/LRP2 and the regulation of its functional expression. Biol Res. 2011;44(1):89–105.
36. Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci U S A. 1995;92(10):4537–41.
37. Bu G, Geuze HJ, Strous GJ, Schwartz AL. 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J. 1995;14(10):2269–80.
38. Narita M, Bu G, Herz J, Schwartz AL. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest. 1995;96(2):1164–8.
39. Sinitsyn VV, Mamontova AG, Checkneva YY, Shnyra AA, Domogatsky SP. Rapid blood clearance of biotinylated IgG after infusion of avidin. J Nucl Med. 1989;30(1):66–9.